Skip to main content
ILYANG PHARMACEUTICAL CO.,LTD logo

ILYANG PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 007570 ISIN · KR7007570005 KO Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 007570

About ILYANG PHARMACEUTICAL CO.,LTD

https://www.ilyang.co.kr

Ilyang Pharmaceutical, established in 1946, is a research-oriented company that develops and manufactures a diverse portfolio of pharmaceutical products. The company focuses on developing new chemical entities (NCEs) and produces a range of medicines targeting digestive, respiratory, and circulatory system disorders, as well as neoplasms and infectious diseases. Key developments include 'Ilaprazole' (Noltec), a proton pump inhibitor for acid-related disorders, and 'Supect' (Radotinib), a treatment for chronic myeloid leukemia. Its product line also encompasses general drugs, antibiotics, anti-inflammatory agents, nutritional supplements, and well-established consumer health brands like the digestive aid 'NORUMO' and the nutritional drink 'Wonbi-D'.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 93% confidence The document is a comprehensive quarterly report (“분기보고서”) covering the 1st quarter of the 56th fiscal year (2026 Jan 1–Mar 31). It includes full financial statements (summary financial information, consolidated and standalone financials, notes), management discussion & analysis, auditor’s opinion, business overview, and segment performance. This matches the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-15 Korean
타법인주식및출자증권취득결정
M&A Activity Classification · 80% confidence The document is a formal stock exchange-style disclosure titled “타법인 주식 및 출자증권 취득결정” (Decision to Acquire Equity Securities of Another Corporation). It details the target company, purchase amount, equity ratio, acquisition method, schedule and business rationale. It is not a financial report (10‐K, IR), not a dividends notice, not a management change, not a buyback of its own shares, nor a routine regulatory certification. Rather, it constitutes an M&A‐style investment decision (acquisition of a subsidiary’s shares). Under our taxonomy, such strategic acquisition announcements fall under “M&A Activity” (TAR).
2026-05-14 Korean
기타경영사항(자율공시)
Regulatory Filings Classification · 80% confidence The document is a voluntary ad-hoc disclosure (“기타 경영사항(자율공시)”) about the dissolution of a subsidiary and transfer of its shares, not a formal audit, earnings release, board change, dividend notice, or proxy material. It does not include board or management changes (MANG), detailed vote counts (DVA), share issuance or buyback (SHA/POS), or M&A proposals (TAR). It is a general regulatory announcement of corporate event details, so it falls into the fallback category “Regulatory Filings (RNS).”
2026-04-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 95% confidence The document is a Korean regulatory filing titled “임원·주요주주 특정증권등 소유상황보고서” submitted to the Financial Supervisory Commission and Korea Exchange. It details an executive’s (Song Hwa-jun) ownership and changes in shareholdings of Ilyang Pharmaceutical Co., Ltd. This corresponds to an insider transaction report by a company director/executive, matching the Director’s Dealing category.
2026-04-06 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is the formal notice of the results of the company’s Annual General Meeting (정기주주총회결과), detailing the resolutions passed, vote counts and percentages, elected directors, dividend approvals, and other shareholder vote outcomes. This aligns exactly with the definition of Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-03-26 Korean
기타경영사항(자율공시)
Governance Information Classification · 85% confidence The document is a voluntary disclosure (“기타 경영사항(자율공시)”) by Ilyang Pharmaceutical outlining a comprehensive corporate governance improvement plan: installation of board committees, appointment of independent directors, resignations of key executives to strengthen accountability, and enhancement of internal controls and audit functions. This is not an earnings release or dividend notice, nor simply a board member appointment form. It describes governance structure, internal rules, and processes. Therefore, it falls under Governance Information (CGR).
2026-03-25 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.